{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:57:21Z","timestamp":1784606241716,"version":"3.55.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Extravasation of the radiopharmaceutical during peptide receptor radionuclide therapy infusion is an unwanted infrequently reported event. We present the case of a 74-year old woman with a neuroendocrine tumor who was referred for peptide receptor radionuclide therapy. During intravenous infusion of 7.4 GBq [<jats:sup>177<\/jats:sup>Lu]Lu-HA-DOTATATE in the upper right arm, extravasation of the radiopharmaceutical occurred through a displaced intravenous catheter. Planar scintigraphy showed pooling of radioactivity in the right upper arm. After 24 hours, the swelling in the arm was decreased; however, erythema was increased. One week later, symptoms had disappeared, and the patient did not experience any complications during follow-up of 11 months.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005137","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T14:00:41Z","timestamp":1710165641000},"page":"454-456","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Extravasation After [177Lu]Lu-HA-DOTATATE Therapy"],"prefix":"10.1097","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-8148","authenticated-orcid":false,"given":"Daphne M. V.","family":"de Vries-Huizing","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zing J.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J. M. A.","family":"Hendrikx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2028-9713","authenticated-orcid":false,"given":"Maarten L.","family":"Donswijk","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle W. J.","family":"Versleijen","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40658-020-00308-9","article-title":"A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy","volume":"7","year":"2020","journal-title":"EJNMMI Phys"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/HP.0000000000001558","article-title":"Lutetium-177 radiopharmaceutical therapy extravasation lessons learned","volume":"123","year":"2022","journal-title":"Health Phys"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s00259-017-3675-7","article-title":"Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13550-020-00658-6","article-title":"Extravasation of [177Lu]Lu-DOTATOC: case report and discussion","volume":"10","year":"2020","journal-title":"EJNMMI Res"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/RLU.0000000000003452","article-title":"Effective management of 177Lu-DOTA0-Tyr3-octreotate extravasation","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40644-022-00467-1","article-title":"Post-PRRT scans: which scans to make and what to look for","volume":"22","year":"2022","journal-title":"Cancer Imaging"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5603\/NMR.a2022.0030","article-title":"Amino acid extravasation: a rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE","volume":"25","year":"2022","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/tomography8010029","article-title":"Cutaneous management after extravasation of high-concentrated amino acid solution administered for renal protection in PRRT","volume":"8","year":"2022","journal-title":"Tomography"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40658-021-00378-3","article-title":"Tissue dose estimation after extravasation of 177Lu-DOTATATE","volume":"8","year":"2021","journal-title":"EJNMMI Phys"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:04:15Z","timestamp":1750532655000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005137","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}